AbClon Inc. logo

AbClon Inc.

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The companys products in pipeline include NEST platform technology products for stomach, breast, colorectal, lung, and solid cancers.

Abclon also offers peptide and protein for antibody development; monoclonal antibody service for various antigens comprising peptide, protein, and recombinant proteins; polyclonal antibodes, protein kits and antibody drug development services.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”174900.KQ” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.abclon.com
Founded
Disease Focus
Development Stage
STOCK CODEKOSDAQ: 174900
Address
1401, Ace Twin Tower 285Digital-ro Guro-gu,8381
Seoul
South Korea
Email
Contact Number
+822-2 2109 1924

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

In Nov 2016, AbClon grants Chinese development rigts of AC101, to Shanghai Hanlius Biotech, under the agreement, Hanlius paid US$1 Mn as an upfront and US$15.5 Mn in commission and royalty. Shanghai Hanlius Biotech is a joint venture established by Shanghai Fosun Pharmaceutical and Henlius Biopharmaceutical in 2009.

In June 2013, Affibody AB and AbClon signed a license agreement regarding the use of Affibodys proprietary technology platforms: Affibodyë molecules and AlbumodTM for use in combination with AbClons proprietary and/or generic anti-cancer antibodies.